2019 John A. Catanzaro
Clonal diversity of cancer cells associated with immune evasion, escape, invasive progression and drug resistance characteristically exhibit phenotypic heterogeneity. This results in part from the ability of the cancer cells to switch between phenotypic states. In other words, change in identity (progeny to progeny). Change in antigenic determinant expression creating tolerance and resistance. https://lnkd.in/fJDHfkK
The diversity of cancer cell phenotypes within individual tumors plays a major role in driving immune evasion, escape, invasive progression and drug resistance. Individual cancer cell mutation and migratory patterns are also driving forces to the diversity of the tumor microenvironment. In support of this model, there are significant genetic differences between different sections of a tumor, and even across different cells from the same tumors. https://lnkd.in/fw8EmZD
DNA barcoding to track phenotypical changes and label a diverse catalogue of clone varieties to assess changes in cell type and tumor patterns can interrogate changing plasticities. https://lnkd.in/fJnjGSf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356442/#!po=8.82353
Cancer Hallmark Analytics and Immunocentric engineering integrates interrogation profiling to determine cancer cell and tumor microenvironment behavior and changes for downstream patient precision-based treatment immune innovation.